CLINICAL CASE

Bilateral swelling of the salivary glands and sicca symptoms: an unusual differential diagnosis—Kimura’s disease, a rare allergic condition with a high IgE serum level—a case report and review of the literature

Jürgen Braun,1 Thomas Mairinger,2 Oliver Kaschke,3 Kai Behrendt,4 Josef Ramsbacher,5 Kirsten Karberg6

ABSTRACT

A 68-year-old woman presented with bilateral swelling of the salivary glands, sicca symptoms of eyes and mouth, itching, fatigue and weight gain of about 5 kg in the last 2–3 years. As part of a careful diagnostic work up including lab tests for antinuclear antibodies (ANA), antibodies to extractable nuclear antigens (ENA), anti-neutrophilic cytoplasmatic antibodies (ANCA), immunoglobulin (Ig)G4, a whole body computed tomography (CT) and a parotid biopsy several rheumatic diseases such as Sjoegren’s syndrome, IgG4-related disease and sarcoidosis were ruled out and, considering a very high titre of IgE, Kimura’s disease was diagnosed. The case and a short review of the literature are presented.

INTRODUCTION

Inflammatory musculoskeletal rheumatic diseases (RMD) comprise many different symptoms and diseases, some more localised, other with clear systemic features. Features of autoimmunity such as in Sjoegren’s syndrome and of autoinflammation such as in immunoglobulin G4-related disease (IgG4-RD), both systemic immune-mediated fibroinflammatory conditions, may display symptoms related to the salivary glands such as xerostomy. The pathogenesis of these diseases is incompletely understood, and this is similar for allergic diseases, which are generally different in terms of symptoms and pathomechanisms, but swelling of salivary glands does also, even though rarely, occur. One case is described here.

Since both, rheumatic and allergic diseases, show a pathophysiologically relevant involvement of the immune system, knowledge about allergic diseases matters also for rheumatologists. In addition, the frequency of atopic disorders in RMD has been of interest in this regard, and this was related to differences in cytokine patterns based on the TH1/TH2 paradigm. Indeed, it is now well established that IgE-dependent allergies are TH2 driven. The TH2 branch of the adaptive immune system favours CD4+TH2 cells, eosinophils, basophils, mast cells, type 2 innate lymphoid cells as well as the production of cytokines such as IL-4, IL-5, IL-9 and IL-13 and humoral antibody responses of the immunoglobulin antibody IgE isotype. Monomers of this antibody which is found only in mammals are synthesised by plasma cells and they consist of two heavy and two

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Kimura’s disease has been largely ignored in the rheumatologic literature. Most publications have been released by other specialties.

WHAT THIS STUDY ADDS

⇒ This report shows that Kimura’s disease is an important rheumatologic differential diagnosis because the symptoms may resemble Sjoegren’s disease, IgG4 associated disease and sarcoidosis.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Rheumatologists will likely ask more intensively for allergic symptoms such as itching and order IgE lab tests - especially in cases which present with symptoms suggestive of Sjoegren’s syndrome but lab results for ANA and IgG4 were normal.
light chains. IgE, discovered in 1967, is thought to be important for the immune response against infections by certain parasitic worms. However, it is also essential for type I hypersensitivity reactions that manifest in various allergic diseases such as allergic asthma and rhinitis, food allergies, chronic urticaria and atopic dermatitis. IgE also plays a pivotal role in responses to allergens, such as: anaphylactic reactions to drugs, bee stings and antigen preparations used in desensitisation immunotherapy. In allergic conditions, high titres of IgE are observed—and this was also the case in the patient we describe here.

Food allergy is an inadequate response of the immune system to an antigen, in the majority of cases of a protein nature, ingested in food, that is often accompanied by the synthesis of IgE antibodies directed at allergens. These bind to type I high-affinity IgE receptors (FcεRI) on mast cells and basophils, sensitising them to contact a cognate allergen. This promotes the release of a large variety of inflammatory mediators including histamine which are responsible for the symptoms of immediate hypersensitivity. Histamine is a neuro-immuno-endocrine system mediator, which influences a whole spectrum of physiologic functions of various tissues and cells, including immunity. The half-life of histamine in plasma is relatively short, a few minutes. Histamine is metabolised in several pathways in the organism, the most important one is by diamine oxidase (DAO, 5). An elevated histamine and a low DAO level were also found in our patient.

CASE REPORT

A 68-year-old woman born in Bulgaria (figure 1) presented with bilateral swelling of the salivary glands, sicca symptoms of eyes and mouth, itching, weight gain of about 5 kg in the last 2–3 years, pain and dysesthesia in the left upper arm and fatigue which had already been ongoing for almost 2 years. Degenerative changes in the cervical spine had been documented and a mild carpal tunnel syndrome had been diagnosed about 18 months ago. A current repetition of the test showed that it is still present and now a bit worse.

Without a clear diagnosis, she had been treated with glucocorticoids elsewhere with some transient success for a short period of time some weeks ago. The patient had obstructive sleep apnea (OSA) since several years which is currently treated with a continuous positive airway pressure device. Because of a history of atrial fibrillation (probably related to OSA) and a pacemaker implantation, she could not undergo magnetic resonance imaging (MRI). A computed tomography (CT) confirmed diffuse swelling of the salivary glands without signs of lymphoma (figure 2). The first diagnostic work up revealed a diffuse swelling of the salivary glands normal laboratory parameters including blood count, liver enzymes, creatinine, antinuclear antibodies (ANA), antibodies to extractable nuclear antigens (ENA), IgG4, thyroid stimulating hormone (TSH), creatine kinase (CK), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and a urine analysis and a normal chest radiograph. The second work up included CTs of the chest and the abdomen, only showing knotty changes in the right thyroid gland and an incidentaloma in the left adrenal gland. In addition, a high IgE level (almost 3,000 units)— commissioned because of the strong itching complained by the patient - and a slight eosinophilia (7%) were detected, while CRP, ANCA and complement levels were in the

Figure 1  The patient.

Figure 2  CT of the head showing bilaterally enlarged parotid glands (A) overview (arrows), (B) parotid glands, (C) submandibular glands. Red left, green right. The CT scan shows slightly enlarged parotid and submandibular glands (arrows) on both sides, with some differences in volume between sites.
normal range. The patient was symptomatically treated with 10 mg of desloratadine to make itching more tolerable and 1000 mg of novamisulfone for the pain in the left arm with some success. A parotid gland biopsy was performed, which showed lymphocytic and eosinophilic infiltrates with fibrotic changes, while there was no sign of Sjogren’s syndrome, IgG4-related disease or sarcoidosis, but CD3, CD20 and plasma cell (Mum1) stainings demonstrated that the cellular infiltrates seen in the haematoxylin and eosin staining consisted mainly of T and B cells (figure 3A–D). These infiltrates were not close to the ducts of the salivary gland but rather diffuse tissue infiltrates. No ultrasound of the salivary glands was performed. After an intensive study of the literature, a diagnosis of Kimura’s disease was made.

A relatively large number of patients with Kimura’s disease has been described earlier (see references), but we confess that we did not know the disease, and we have not seen a similar case in the last decades.

After the initial treatment with desloratadine had improved symptoms, especially itching, we prescribed a course of prednisolone starting with 1 mg/kg consequently tapered down within a few weeks. However, this was not really successful regarding general symptoms but there were typical side effects. Nevertheless, the eosinophil count went down and there was the impression that the enlargement of the glands had improved after 6 weeks. However, the patient insisted to discontinue prednisolone, and the IgE level was even a bit higher than initially.

A decision was made to first repeat the allergy tests which had been normal 4 years ago.

Serologic testing (Fluoreszenz-Enzym-Immunoassay, Fa. Thermo Fisher) revealed an allergic reaction against mugwort, chicken and milk protein. The serum level of histamine was slightly elevated (1.2 ng/mL), while the level of diaminooxidase was low (5.9 U/mL).

At first, it was found that there is currently no bad need to treat with immunosuppressives or anti-IgE or anti-IL-4/13 antibodies, and the patient did not want to take those drugs.

**DISCUSSION**

A case of Kimura’s disease is reported because it represents a rare differential diagnosis to important inflammatory RMD, namely primary Sjogren’s syndrome, IgG4-related disease and even eosinophilic granulomatosis with polyangiitis. There was no evidence for a hyper IgE-syndrome either.

Head and neck involvement has been described in many RMD patients. The differential diagnosis of IG4-related sialadenitis and Kimura’s disease has been recently studied and discussed in much detail based on 85 cases with IgG4-related disease and 52 with Kimura’s disease. In IgG4-related disease, the vast majority of cases had enlargement of multiple salivary and/or lacrimal glands and most patients had bilateral submandibular gland involvement. In Kimura’s disease, unilateral parotid gland involvement and comorbid skin lesions were present in more than half of the patients. In IgG4-related disease, serum IgG4 levels were elevated in >90% of cases versus only in 19% in Kimura’s disease.
Elevated eosinophil counts and elevated IgE concentrations were found in most patients with Kimura’s disease (86% and 96%, respectively) but also, even though less frequently, in IgG4-related disease (23% and 77%, respectively). In the latter, storiform fibrosis, irregular lymphoid follicles and increased IgG4-positive cells were common, while acellular fibrosis, regular lymphoid follicles, IgE-positive reticular networks, increased IgE-positive cells and tryptase-positive mast cells were more often detected in Kimura’s disease. In addition, in IgG4-related disease, lymphoplasmacytic infiltration and obliterator phlebitis have been described as being rather characteristic. Involved of specific T cells has been described in Kimura’s disease, and many differences in comparison to IgG4-related disease. Taken together, there were several overlapping manifestations in that study, but histopathological examination revealed meaningful differences in the types of fibrosis, eosinophils and IgG4-positive cell counts.

In our patient, the leading symptoms were swelling of the face and itching. The main lab finding was a high IgE titre. Salivary glands were enlarged and the parotid biopsy revealed eosinophilic and lymphocytic infiltrates with some fibrosis. There was no expression of IgG4, there were no granulomas (sarcoidosis) and no foci according to Chisholm and Mason suggestive of Sjoegren’s syndrome.

A first publication of Kimura’s disease occurred already in 1937 in a Chinese medical journal. Accordingly, the disease has been described more often in Asians, but it does occur in non-Asians with a similar clinicopathologic presentation. It is a distinctive entity with no known aetiology that reportedly occurs more frequently in Asia where it affects more male patients, and lymph node involvement is common.

The differential diagnosis of Kimura’s disease also includes angiolymphoid hyperplasia with eosinophilia, angioimmunoblastic T-cell lymphoma, Hodgkin lymphoma, Langerhans cell histiocytosis, Castleman disease, florid follicular hyperplasia, dermatopathic lymphadenopathy, drug reaction, tumour node metastases and parasitic lymphadenitis.

At the centre of the pathogenesis of allergic diseases is the IgE antibody molecule. The physiological function of IgE is to provide protective immunity against helminth parasites, but it can also mediate type I hypersensitivity reactions that contribute to the pathogenesis of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis. However, despite IgE causing an abundance of human disease, it was not until 1967 that the molecule was discovered, and this is in part due to its very low serum concentration relative to other antibody isotypes—over one hundred thousand-fold less than IgG in healthy individuals. Despite the importance of IgE in immune biology and allergic pathogenesis, the cells and the pathways that produce and regulate IgE in detail are poorly understood. In sensitised individuals, re-exposure to the allergen results in IgE engagement, causing Fce receptor cross-linking and activation of mast cells and basophils. The two primary vasoactive mediators histamine and cysteinyl-leukotrienes which are released by eosinophils, T cells, mast cells and basophils regulate the production of IgE on a local and systemic level. This triggers the release of mediators into the local tissue, leading to a broad array of immediate symptoms associated with allergy. Chronic allergic inflammation is often associated with raised IgE titres which are normally <100 U/mL, but the frequency of IgE-producing memory B cells in peripheral blood is exceedingly low. Studies of the human IgE molecule, and its targeted epitopes on allergens, have been rather limited to date.

The serologic examination revealed an allergic sensitisation to mugwort, chicken and milk protein and an increased serum level of histamine together with a low level of DAO—a finding frequently reported in food intolerance, a non-allergic food hypersensitivity, treated with low-histamine diet. A good response to such a diet confirms the diagnosis. Alongside the dietary measures, DAO supplementation supporting the degradation of ingested histamine can be tried. In the case of our patient, allergen avoidance was recommended.

The anti-IgE monoclonal antibody omalizumab that binds to free IgE in the blood, and inhibits the activation of inflammatory mechanisms, has already been approved to treat severe asthmatic conditions many years ago. Since Kimura’s disease is suspected to be an IgE-mediated allergic disorder, a pilot study with omalizumab has indeed been performed. Three patients received a fixed schedule of 8 cycles of omalizumab 300 mg subcutaneous (s.c.) at intervals of 2 weeks. With that therapy, the size of the masses and peripheral blood eosinophil counts decreased. However, omalizumab may not work well in patients whose total serum IgE levels are >1500 U/mL.

In another case, report on a patient with Kimura’s disease oral glucocorticoids had been administered for 1 year, but the masses recurred as the dosage was tapered down. Subsequently, anti-IgE therapy with omalizumab was administered at 450 mg s.c. at 4-week intervals. The size of the masses, the serum IgE level and the percentage of eosinophils did not decrease significantly after 19 cycles of continuous treatment. Thereafter, dupilumab, a monoclonal antibody blocking IL-4 and IL-13 that is approved for allergic diseases such as atopic dermatitis, was administered in an initial dose of 600 mg, followed by 300 mg every 2 weeks for 4 months. This treatment demonstrated dramatic effects with reduced masses and fast dropout of eosinophil counts, while the high level of serum IgE remained high.

Taken together, the clinical picture of Kimura’s disease differs and therapy is not straightforward, but there are developments, especially with anti-IgE and anti-IL-4/IL-13 antibodies. Surgical procedures and radiotherapy have also been successfully used, especially in patients with large masses. However, several reports
also stress that the course of the disease may be rather benign—even with no specific therapy.33

The further course of the disease will be challenging, we are ready to try dupilumab in this patient who clearly has a reduced quality of life but is now considering to try a biologic drug.

Author affiliations
1Rheumapraxis Berlin, Ruhr University Bochum, Berlin, Germany
2Dept. of Pathology, Medizinisches Versorgungszentrum am Helios Klinikum Emil von Behring, Berlin, Germany
3Dept of Otorhinolaryngology, St. Gertraud Krankenhaus, Humboldt-Universität zu Berlin, Berlin, Germany
4Roentgenpraxis Radiologie Eins, Humboldt-Universität zu Berlin, Berlin, Germany
5Praxis für Neurochirurgie, Humboldt-Universität zu Berlin, Berlin, Germany
6Rheumapraxis Berlin, Humboldt-Universität zu Berlin, Berlin, Germany

Acknowledgements We acknowledge the contribution of Prof.B.Tebbe who made the allergy tests and Prof.M.Laniodo who gave advice for imaging interpretation.

Contributors All authors have contributed. In detail, JB and KK have made the diagnosis, are responsible for patient management and have written the manuscript. TM has been responsible for the (immuno)histology, OK has made the parotid biopsy, KB has been responsible for imaging and JR has made the neurological examination and has referred the patient to rheumatology.

Funding We acknowledge support by the Open Access Publication Funds of the Ruhr-Universität Bochum and the Rheumazentrum Ruhrgebiet.

Competing interests None declared.

Patient consent for publication Consent obtained directly from patient(s).

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Juergen Braun http://orcid.org/0000-0002-9156-5095

REFERENCES